Is This Flaming Hot Biotech Stock a Buy?
On June 4, small-cap biotech company Kezar Life Sciences (NASDAQ: KZR) announced updated phase 1/2 results from a clinical study evaluating KZR-616 for the treatment of patients with systemic lupus erythematosus (SLE) with and without lupus nephritis (LN). Investors seemed to like the data. By the market's close, shares were up 73.38% to $7.75, pushing the company's market cap toward $300 million. The following week, shares had settled back down to $5.58.
Will the company become a maverick in developing a therapeutic candidate for this significant medical need? Let's find out.
Image source: Getty Images.
Source Fool.com
